255
Participants
Start Date
September 30, 2005
Primary Completion Date
December 31, 2010
Study Completion Date
December 31, 2010
fluocinolone acetonide intraocular implant
RETISERT™ (fluocinolone acetonide intravitreal implant) 0.59 mg is a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye at a nominal initial rate of 0.6 μg/day, decreasing over the first month to a steady state between 0.3-0.4 μg/day over approximately 30 months.
oral corticosteroid with immunosuppressive agents as needed
Prednisone
New York Eye and Ear Infirmary, New York
Scheie Eye Institute, University of Pennsylvania, Philadelphia
National Eye Institute, NIH, Bethesda
Wilmer Eye Institute, Johns Hopkins University, Baltimore
Virginia Eye Consultants, Norfolk
Duke Eye Center, Duke University, Durham
Emory University, Atlanta
Anne Bates Leach Eye Hospital, University of Miami Miller School of Medicine, Miami
University of South Florida, Tampa
Kellogg Eye Center, University of Michigan, Ann Arbor
Rush University Medical Center, Chicago
University of Illinois at Chicago Eye Center, Chicago
Barnes Retina Institute, St Louis
Texas Retina Associates, Dallas
Vitreoretinal Consultants, Houston
John A. Moran Eye Center, University of Utah, Salt Lake City
Doheny Eye Institute, USC, Los Angeles
Jules Stein Eye Institute, UCLA, Los Angeles
Jacobs Retina Center, UCSD, La Jolla
Proctor Foundation, UCSF, San Francisco
Massachusetts Eye Research & Surgery Institute, Cambridge
Royal Victoria Eye & Ear Hospital, East Melbourne
United Kingdom Institute of Ophthalmology, London
Lead Sponsor
National Eye Institute (NEI)
NIH
JHSPH Center for Clinical Trials
OTHER